Institution · Centre Hospitalier du Mans

Most cited papers from Centre Hospitalier du Mans

Centre Hospitalier du Mans

What are the most cited papers from Centre Hospitalier du Mans?

The most cited paper from Centre Hospitalier du Mans is "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial" (Rafael Rosell et al., 2012), with 5,563 citations. Next come "Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome" (2,451) and "High versus Low Blood-Pressure Target in Patients with Septic Shock" (1,248).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 204 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Rafael Rosell et al. · The Lancet Oncology Open access	30 Jan 2012	5,563
2	Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome Alain Combes et al. · New England Journal of Medicine Open access	23 May 2018	2,451
3	High versus Low Blood-Pressure Target in Patients with Septic Shock Pierre Asfar et al. · New England Journal of Medicine Open access	18 Mar 2014	1,248
4	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Federico Cappuzzo, Tudor–Eliade Ciuleanu, Lilia V. Stelmakh et al. · The Lancet Oncology Open access	21 May 2010	1,194
5	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial Gérard Zalcman et al. · The Lancet	22 Dec 2015	980
6	Eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): Clinical characteristics and long‐term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort Cloé Comarmond et al. · Arthritis & Rheumatism	8 Oct 2012	937
7	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases Brad H. Rovin et al. · Kidney International Open access	20 Sep 2021	823
8	Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial Andrew H. Wei et al. · Blood Open access	27 Mar 2020	774
9	Antineutrophil Cytoplasmic Antibodies and the Churg–Strauss Syndrome R. Sablé-Fourtassou, Pascal Cohen, Alfred Mahr et al. · Annals of Internal Medicine	Nov 2005	688
10	Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis Christian Pagnoux, Alfred Mahr, Mohamed Amine Hamidou et al. · Yearbook of Medicine	24 Dec 2008	674
11	Targeted Temperature Management for Cardiac Arrest with Nonshockable Rhythm Jean-Baptiste Lascarrou et al. · New England Journal of Medicine Open access	2 Oct 2019	669
12	Epidemiology of Weaning Outcome according to a New Definition. The WIND Study Gaëtan Beduneau, Tài Pham, Frédérique Schortgen et al. · American Journal of Respiratory and Critical Care Medicine	14 Sep 2016	651
13	Whipple's Disease Florence Fenollar, Xavier Puéchal, Didier Raoult · New England Journal of Medicine	4 Jan 2007	643
14	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial P. Joly et al. · The Lancet	22 Mar 2017	622
15	Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Luis G Paz-Ares, Filippo de Marinis, Mircea Dediu et al. · The Lancet Oncology Open access	16 Feb 2012	617
16	Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2) Jean Reignier et al. · The Lancet 115 authors	8 Nov 2017	592
17	Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial Élisabeth Quoix et al. · The Lancet	13 Aug 2011	578
18	Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications Pierre Nahon et al. · Gastroenterology Open access	16 Sep 2016	540
19	Comorbidities of COPD Arnaud Cavailles, Graziella Brinchault-Rabin, Adrien Dixmier et al. · European Respiratory Review Open access	29 Nov 2013	523
20	Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients Fabrice Denis, Claire Lethrosne, Nicolas Pourel et al. · JNCI Journal of the National Cancer Institute Open access	15 Feb 2017	519
21	Membranous nephropathy Pierre Marie Ronco, Laurence H. Beck, Hanna Dêbiec et al. · Nature Reviews Disease Primers Review	30 Sep 2021	476
22	Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial Arnaud Scherpereel et al. · The Lancet Oncology Open access	16 Jan 2019	458
23	Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study Noopur S Raje, Evangelos Terpos, Wolfgang Willenbacher et al. · The Lancet Oncology	9 Feb 2018	450
24	Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS) Xavier Mariette, Philippe Ravaud, Serge Daniel Steinfeld et al. · Arthritis & Rheumatism	Apr 2004	437
25	Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France Thierry Lequerré, Pierre Quartier, David Rosellini et al. · Annals of the Rheumatic Diseases Open access	19 Oct 2007	406
26	Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial Jean‐Michel Constantin et al. · The Lancet Respiratory Medicine Open access	6 Aug 2019	402
27	Treatment of Churg‐Strauss syndrome without poor‐prognosis factors: A multicenter, prospective, randomized, open‐label study of seventy‐two patients Camillo Ribi, Pascal Cohen, Christian Pagnoux et al. · Arthritis & Rheumatism Open access	31 Jan 2008	335
28	Prospective Evaluation of Magnetic Resonance Imaging and [ 18 F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study Philippe Moreau et al. · Journal of Clinical Oncology Open access	7 Jul 2017	329
29	Plant-based diets to manage the risks and complications of chronic kidney disease Juan Jesús Carrero, Ailema González-Ortíz, Carla María Avesani et al. · Nature Reviews Nephrology ReviewOpen access	11 Jun 2020	322
30	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study Alice Tison et al. · Arthritis & Rheumatology Open access	5 Aug 2019	321
31	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial William W. Busse et al. · The Lancet Respiratory Medicine 460 authors	8 Nov 2018	316
32	Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. G Magadur-Joly, Éric Billaud, J.-H. Barrier et al. · Annals of the Rheumatic Diseases Open access	Jul 1995	313
33	Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial Pierre Asfar et al. · The Lancet Respiratory Medicine	15 Feb 2017	311
34	Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES) Rima Nabbout, Michel Mazzuca, Philippe Hubert et al. · Epilepsia	31 Aug 2010	311
35	Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib David Ghez, Anne Calleja, Caroline A. Protin et al. · Blood	Feb 2018	309
36	Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Case–Control Study Sylvie Bastuji‐Garin, P. Joly, Pauline Lemordant et al. · Journal of Investigative Dermatology Open access	14 Oct 2010	303
37	Vasculitides associated with malignancies: Analysis of sixty patients Olivier Fain et al. · Arthritis Care & Research	29 Nov 2007	299
38	Sleep Apnea–Specific Hypoxic Burden, Symptom Subtypes, and Risk of Cardiovascular Events and All-Cause Mortality Wojciech Trzepizur, Margaux Blanchard, Timothée Ganem et al. · American Journal of Respiratory and Critical Care Medicine	14 Oct 2021	296
39	Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry Dominique Salmon‐Céron, Florence Tubach, Olivier Lortholary et al. · Annals of the Rheumatic Diseases	21 Dec 2010	286
40	Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial Stèphane Gaudry et al. · The Lancet Open access	Apr 2021	285
41	VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial Philippe Moreau et al. · Blood Open access	21 Mar 2016	280
42	Symptoms of Anxiety, Depression, and Peritraumatic Dissociation in Critical Care Clinicians Managing Patients with COVID-19. A Cross-Sectional Study Élie Azoulay et al. · American Journal of Respiratory and Critical Care Medicine Open access	31 Aug 2020	279
43	Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing Claire E. Redin et al. · Journal of Medical Genetics Open access	28 Aug 2014	277
44	Eprodisate for the Treatment of Renal Disease in AA Amyloidosis Laura M. Dember, Philip Nigel Hawkins, Bouke P. C. Hazenberg et al. · New England Journal of Medicine	6 Jun 2007	274
45	Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3) Jean Reignier et al. · The Lancet Respiratory Medicine Open access161 authors	20 Mar 2023	270
46	High-flow nasal cannula oxygen during endotracheal intubation in hypoxemic patients: a randomized controlled clinical trial Mickaël Vourc’h, Pierre Asfar, Christelle Volteau et al. · Intensive Care Medicine Open access	13 Apr 2015	265
47	Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study Michael Joseph Boyer et al. · Journal of Clinical Oncology Open access	29 Jan 2021	261
48	Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial Raphaèle Séror, Gabriel Baron, Eric HACHULLA et al. · Annals of the Rheumatic Diseases	29 Jul 2013	255
49	Effect of Influenza Vaccination of Nursing Home Staff on Mortality of Residents: A Cluster‐Randomized Trial Magali Lemaître, Thierry Meret, Monique Rothan‐Tondeur et al. · Journal of the American Geriatrics Society	4 Aug 2009	254
50	Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty‐five patients Loïc Guillevin, Pascal Cohen, Alfred Mahr et al. · Arthritis Care & Research	7 Feb 2003	253

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.